also..-HFBG_IAGM_MGRND_NEPT-BISU-ONTC-AVEW-HPNN_EMLL_POTG_SKNY- HYII-GBKVF/VSHC-AWYI_EGOC-RNRG-SAVW NVAE SDVI WTFS VLCO this is my check and play list HFBG Today as yesterday !!We need to break eight 0.001 Will Be nice monday
NEPT UPDATE and ARGEF UPDATE__Ladies and Gentlemen, We suggest that you take a close look at Neptune Technologies &Bioressources Inc.The company's fundamentals have been improving at an impressive paceover the past couple of months, and we believe we are on the verge ofseeing new yearly highs on the stock price. For more details on the company, consult their website:www.neptunebiotech.com
Have a great day,
must read!!!!!!!!!Argex's La Blache Titanium Dioxide Achieves Outstanding Brightness and Colour Results on the Cielab Colour Space
2011-07-20 15:17 ET - News Release
Argex's La Blache Titanium Dioxide Achieves Outstanding Brightness and Colour Results on the Cielab Colour Space Canada NewsWire
MONTREAL, July 20, 2011
MONTREAL, July 20, 2011 /CNW Telbec/ - Argex Mining Inc. ("Argex") (TSXV: RGX) (FSE: ASV) (OTCBB: ARGEF) announced today preliminary brightness and colour results from samples of its La Blache ilmenite titanium dioxide ore processed using the CTL technology developed by Process Research Ortech (PRO). Test results on samples of Argex's uncoated TiO2 pigment compare favourably with results obtained on standard products made by leading TiO2 producers. Brightness ("L*") and colour ("a* and b*") measurements are indicators of the effectiveness of the process technology employed in removal of trace amounts of impurities. The outstanding brightness and colour figures obtained on the Argex products indicate that the CTL process is fully capable of producing high purity TiO2 base products that are competitive with products made from traditional TiO2 manufacturing processes. Argex TiO2 pigment samples tested achieved competitive L* average brightness levels of 99.69 and 99.87. Better than competitive product average b* values indicate that the CTL process is able to produce a clean base TiO2 product.
These results, along with all other results reported below were obtained using a BYK Spectro-Guide instrument (www.byk.com/en/instruments/color/solid-color.html) by PRO The La Blache titanium dioxide samples were produced from the mini-plant at PRO's facility in Mississauga, Ontario, where La Blache ore samples were crushed, leached, extracted using organic solvent extraction, precipitated and calcined prior to analysis. The mini-plant has been operational since February 14, 2011.
The Commission international de l'éclairage (CIE), or International Commission on Illumination in English, known as CIELAB (CIE L* a* b*), is the most complete colour instrument that describes colours visible to the human eye and was created to serve as a device independent model to be used as a reference.
"Argex's TiO2 pigment has achieved brightness results that are in line with or superior to some of the major TiO2 industry producers in testing to date", states Argex President and CEO Roy Bonnell, "Argex believes that our CTL technology is a highly competitive process for extracting TiO2 from ilmenite ore. Argex expects that the CTL process will be a low cost and environmentally friendly process for producing high purity TiO2 products."
CTL Agreement Expected To Be Finalized In The Near Term
On February 14, 2011, Argex announced it had signed a letter of intent (LOI) with the principals of Canadian Titanium Ltd. (CTL) for the purchase of up to a 50.1% interest in CTL. All parties to the LOI have confirmed that it is their expectation that the definitive agreement will be executed shortly on the same terms and conditions as previously announced.
Additional information on the equipment used, and the CEILAB colour space can be found at the links below, including detailed definition "L*", "a*" and "b*".
ARGEX MINING INC. is transitioning from a titanium, iron and vanadium explorer to a development company with projects in Quebec, Canada. The Company is committed to its strategic plan of rapidly advancing towards profitable production at its 100% owned La Blache deposits located near Baie-Comeau, Quebec. For additional information please visit our website at www.argex.ca.
Also IAGM Closing is_anticipated_to_occur_in_August_2011. !!!!!!!..probably a rebound soon.. IAGM(15:58)2011-07-07_News Release_nice$$$$$$$$ InterAmerican Gaming to Acquire NOWPHIT
TORONTO, ONTARIO -- (MARKET WIRE) -- 07/07/11
InterAmerican Gaming Inc. ("the Company") (OTCBB: IAGM) announced today that it has entered into a letter of intent with Baron Group Ventures ("BGV") to acquire an 80.1% interest in NOWPHIT (www.nowphit.com). NOWPHIT is a new social gaming platform and smartphone application that empowers and inspires people to improve their personal health and fitness and makes it easier to achieve healthy lifestyle goals. The NOWPHIT app will be available for the iPhone via the iTunes Store at launch (expected Q4 2011), with Blackberry and Android versions to follow.
NOWPHIT syncs with gym or at-home fitness machines and allows "NOWPHIT athletes" to track, train and compete with each other over the NOWPHIT network in real time for virtual and real-life rewards such as trophies, medals and location-based coupons and special offers. NOWPHIT also features a charitable and event function. NOWPHIT athletes can raise donations for a charity of their choice, and virtually train and compete in real athletic events anywhere around the world (i.e. the New York City Marathon).
InterAmerican Gaming is acquiring NOWPHIT by issuing sixty-five million (65,000,000) of its common shares. The terms also require IAGM to exclusively fund the development of NOWPHIT through recourse loans to a maximum of five million dollars (US$5,000,000). At closing, Mr. Marc Askenasi, the founder of NOWPHIT and principal shareholder of BGV, will enter into a management agreement to become Chief Executive Officer of the Company. The closing of the acquisition is subject to mutual due diligence, the completion of the formal purchase and sale documents, and settlement of certain liabilities of the Company. Closing is anticipated to occur in August 2011.
Acasti Pharma Inc. to Welcome Dr. Harlan Waksal
2011-07-21 08:00 ET - News Release
LAVAL, Quebec, July 21, 2011 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti) (TSX-V:APO), a subsidiary of Neptune Technologies & Bioressources Inc., is pleased to announce the nomination of Harlan Waksal M.D. as Executive Vice-President, Business & Scientific Affairs.
Dr. Harlan Waksal will be involved in the execution of the strategic development plan, especially in the clinical development program which will lead to an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) of the United States. Dr. Harlan Waksal will also be involved in other scientific operations as well as in business development.
Dr. Harlan Waksal is a physician, co-founder of ImClone System Incorporated and from 1987 to 2003 he held various positions at the company which included serving on the ImClone Board of Directors, Chief Operating Officer and Executive Vice-President, the President and Chief Executive Officer. At ImClone System Dr. Harlan Waksal was instrumental in guiding the development and obtaining FDA approval for a new targeted biologic cancer therapy known as Erbitux. ImClone Systems was acquired by Eli Lily for $6.5 B US in October 2008. Dr. Harlan Waksal currently serves on the Board of Directors of Oberlin College and Senesco Technologies, Inc. He is the author of over 50 scientific publications and has been the inventor of multiple patents and patent applications.
"I'm very enthusiastic to join the Acasti management team. Acasti is a dynamic and very promising company with amazing potential and I'm looking forward to contribute to its success," stated Dr. Harlan Waksal. "Dr. Harlan Waksal represents a significant addition to the Acasti team; his knowledge, experience, successes and credibility in the pharmaceutical field as well as his credentials in the financial world will contribute to improve, among others, Acasti US presence, US program and to maximize shareholders' value," stated Henri Harland, CEO. "We are very pleased with Harlan's commitment to Acasti," he added.
On the other hand, in compliance with Canadian securities laws, Acasti and its parent company, Neptune Technologies & Bioressources Inc. will be releasing their first quarter financial results under International Financial Reporting Standards (IFRS) on or before August 15, 2011. Under Canadian securities laws, public companies are entitled to use an additional 30 days period to produce their first set of financial statements under IFRS. "Acasti and Neptune results for the three-month period ended May 31st, 2011 are in line with their financial forecasts, and both companies have decided to utilize the extended period allowed for the publication of their financial statements under IFRS because of the additional work load resulting from a transition to new reporting accounting standards," stated Xavier Harland, CFO.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular conditions within the over-the-counter, medical food and prescription drug markets.
About Neptune Technologies & Bioressources Inc.
Neptune (Nasdaq:NEPT) (TSX-V:NTB) is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide. Neptune is the mother company of Acasti and NeuroBioPharm. "Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.
CONTACT: Acasti Contact: Tina Sampalis President +1 450.686.4555 t.sampalis@acastipharma.com www.acastipharma.com
Market Data 
Markets 
AI
